Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEVER Pilot Trial: Hydroxychloroquine and/or Everolimus for Prevention of Recurrent Breast Cancer
NCT03032406Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydroxychloroquine and everolimus in breast cancer (3 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Participants Who Completed 6 Cycles of Protocol Treatment Without Grade 3 or 4 Toxicity at 3 years. Started Jan 2017; status: active, not recruiting.
02
Drugs
hydroxychloroquineeverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03032406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032406.